ES2171878T3 - Derivados de tiazolilbenzofurano y composiciones farmaceuticas que los contienen. - Google Patents

Derivados de tiazolilbenzofurano y composiciones farmaceuticas que los contienen.

Info

Publication number
ES2171878T3
ES2171878T3 ES97900432T ES97900432T ES2171878T3 ES 2171878 T3 ES2171878 T3 ES 2171878T3 ES 97900432 T ES97900432 T ES 97900432T ES 97900432 T ES97900432 T ES 97900432T ES 2171878 T3 ES2171878 T3 ES 2171878T3
Authority
ES
Spain
Prior art keywords
replaced
alcoxi
derivatives
tiazolilbenzofurano
contain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97900432T
Other languages
English (en)
Spanish (es)
Inventor
Masaaki Matsuo
Kazuo Okumura
Shinji Shigenaga
Hiroaki Nishimura
Hiroshi Matsuda
Daijiro Hagiwara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9601235.6A external-priority patent/GB9601235D0/en
Priority claimed from AUPO1111A external-priority patent/AUPO111196A0/en
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2171878T3 publication Critical patent/ES2171878T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES97900432T 1996-01-22 1997-01-17 Derivados de tiazolilbenzofurano y composiciones farmaceuticas que los contienen. Expired - Lifetime ES2171878T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9601235.6A GB9601235D0 (en) 1996-01-22 1996-01-22 Novel compounds
AUPO1111A AUPO111196A0 (en) 1996-07-18 1996-07-18 Novel compounds

Publications (1)

Publication Number Publication Date
ES2171878T3 true ES2171878T3 (es) 2002-09-16

Family

ID=25645218

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97900432T Expired - Lifetime ES2171878T3 (es) 1996-01-22 1997-01-17 Derivados de tiazolilbenzofurano y composiciones farmaceuticas que los contienen.

Country Status (12)

Country Link
US (1) US5994378A (enExample)
EP (2) EP1170009B1 (enExample)
JP (1) JP2000503984A (enExample)
KR (1) KR19990076788A (enExample)
CN (1) CN1209809A (enExample)
AT (2) ATE216384T1 (enExample)
CA (1) CA2244189A1 (enExample)
DE (2) DE69712042T2 (enExample)
EA (1) EA199800650A1 (enExample)
ES (1) ES2171878T3 (enExample)
HU (1) HUP9900424A2 (enExample)
WO (1) WO1997027190A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9919413D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
AU7962200A (en) * 1999-10-29 2001-05-14 Wakunaga Pharmaceutical Co., Ltd Novel indole derivatives and drugs containing the same as the active ingredient
CZ20032829A3 (cs) * 2001-04-16 2005-03-16 Tanabe Seiyaku Co., Ltd. Heterocyklické sloučeniny
WO2003016291A1 (en) 2001-08-10 2003-02-27 Nippon Chemiphar Co., Ltd. ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR δ
MXPA04003398A (es) 2001-10-12 2004-11-22 Nippon Chemiphar Co Activador para el receptor o activado con el proliferador de peroxisoma.
EA200700243A1 (ru) * 2004-07-14 2007-08-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения гепатита с
MX2007004525A (es) * 2004-10-12 2007-09-19 Decode Genetics Inc Sulfonamidas biciclicas peri-sustituidas para enfermedad de arteria oclusiva.
WO2006046683A1 (en) * 2004-10-25 2006-05-04 Astellas Pharma Inc. Thiazolylbenzofuran derivatives as leukotriene and prostaglandin d2 receptor antagonists
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) * 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
AU2007214434B2 (en) * 2006-02-15 2012-06-14 Allergan, Inc. Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
CN101460458A (zh) * 2006-02-15 2009-06-17 阿勒根公司 具有1-磷酸-鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚-3-羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物
EP2014652B1 (en) 2006-04-18 2014-08-06 Nippon Chemiphar Co., Ltd. Activating agent for peroxisome proliferator activated receptor
DE102006021733A1 (de) * 2006-05-09 2007-11-22 Bayer Healthcare Ag 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung
CA2652152A1 (en) * 2006-05-16 2007-11-29 Decode Genetics Ehf Process for preparing 7-(acryloyl)indoles
DE102006043443A1 (de) * 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
EP2125723A1 (en) * 2007-01-11 2009-12-02 Allergan, Inc. 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity
US8524917B2 (en) 2007-01-11 2013-09-03 Allergan, Inc. 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
MX2010011252A (es) 2008-04-15 2010-11-30 Nippon Chemiphar Co Activador para el receptor activado por el proliferador de peroxisoma.
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
NZ601967A (en) 2010-03-12 2015-03-27 Omeros Corp Pde10 inhibitors and related compositions and methods
WO2012087833A1 (en) 2010-12-22 2012-06-28 Abbott Laboratories Hepatitis c inhibitors and uses thereof
CA2901636A1 (en) 2013-02-21 2014-08-28 Adverio Pharma Gmbh Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
HRP20211778T1 (hr) 2014-08-29 2022-03-18 Chdi Foundation, Inc. Kontrastna sredstva za slikovnu dijagnostiku huntingtin proteina
CA2980801A1 (en) 2015-04-24 2016-10-27 Omeros Corporation Pde10 inhibitors and related compositions and methods
CA3003611C (en) 2015-11-04 2022-11-01 Omeros Corporation Solid state forms of a pde10 inhibitor
BR112020009361A2 (pt) 2017-11-17 2020-10-13 Cellix Bio Private Limited composto de fórmula i, composição farmacêutica para tratar um distúrbio ocular ou complicações do mesmo, método de síntese de composto, método de tratamento de um distúrbio ocular ou complicações do mesmo em um indivíduo que precisa do mesmo e uso de um composto

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2600644B2 (ja) * 1991-08-16 1997-04-16 藤沢薬品工業株式会社 チアゾリルベンゾフラン誘導体
JPH07179856A (ja) * 1993-12-21 1995-07-18 Canon Inc 液晶性化合物、これを含有する液晶組成物、該液晶組成物を用いた液晶素子並びにこれらを用いた表示方法、表示装置

Also Published As

Publication number Publication date
EP1170009A3 (en) 2002-01-16
EP0880519B1 (en) 2002-04-17
US5994378A (en) 1999-11-30
ATE216384T1 (de) 2002-05-15
JP2000503984A (ja) 2000-04-04
EP0880519A1 (en) 1998-12-02
WO1997027190A1 (en) 1997-07-31
EP1170009B1 (en) 2004-04-07
DE69712042T2 (de) 2002-10-02
CN1209809A (zh) 1999-03-03
HUP9900424A2 (hu) 1999-05-28
DE69712042D1 (de) 2002-05-23
CA2244189A1 (en) 1997-07-31
EA199800650A1 (ru) 1999-02-25
EP1170009A2 (en) 2002-01-09
ATE263561T1 (de) 2004-04-15
DE69728581D1 (de) 2004-05-13
KR19990076788A (ko) 1999-10-15

Similar Documents

Publication Publication Date Title
ES2150918T3 (es) 1h-imidazo(4,5-c)quinolin-4-aminas 1-sustituidas; compuestos intermedios y composiciones farmaceuticas.
ES2175350T3 (es) Compuestos triciclicos que tienen afinidad de union a receptores de melatonina, su produccion y uso.
ES2170211T3 (es) Compuestos azaheterociclicos que tienen actividad antagonista de los receptores de taquiquinina; nk1 y nk2.
AR029417A1 (es) Bifenil sulfonamidas como antagonistas de receptores de angiotensina endotelina duales
ES2186821T3 (es) Derivados de 6- bencil- 2h-piridazin-3-ona, su preparacion y s u uso como inhibidores de la prostaglandin-g/h sintasa i y ii (cox i y cox ii).
ATE12042T1 (de) Aminosaeurederivate und ihre therapeutische verwendung.
MX9401191A (es) Compuestos del grupo sulfamoilo y amidino, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2196344T3 (es) Derivados de sulfonamida y su uso en el tratamiento de trastornos de snc.
ES2095283T3 (es) Compuestos peptidicos, procedimiento para su preparacion y composicion farmaceutica que los contiene.
BR0114630A (pt) Secretagogos de hormÈnio do crescimento
BR0016166A (pt) Compostos de diidropirimidina heterocìclicos
ES2173172T3 (es) Derivados de 1,3-dihidroindol-2-ona sustituidos en 3 por un grupo nitrogenado como agonistas y/o antagonistas de la vasopresina y/o de la octocina.
ES2189322T3 (es) Intermediarios utiles en la preparacion de inhibidores de encimas.
AR008861A1 (es) COMPUESTOS DE LACTAMA E IMIDA HETEROCICLICOS DE ARALQUILO Y ARALQUILEDENO, COMPUESTOS INTERMEDIARIOS PARA SU SíNTESIS, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN.
ES2193475T3 (es) Composiciones farmaceuticas que contienen derivados de sulfamato como inhibidores de la sulfatasa esteroidea.
ES2184858T3 (es) Cetoenoles alquil-dihalogenofenil substituidos como pesticidas y herbicidas.
ES2195382T3 (es) Compuestos indolcarboxilicos y su uso como compuestos farmaceuticos.
ES2162299T3 (es) Mezclas, que contienen monomeros y estabilizantes.
ES2158076T3 (es) Compuestos 7-(2-imidazolinilamino)quinolinicos utiles como agonistas de alfa-2 adrenoceptores.
ES2132882T3 (es) Compuestos de 1-aril-2-acilamino-etano y su uso como antagonistas de neuroquinina 1.
MX9304424A (es) Bencimidazoles, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
AR013563A1 (es) Composiciones que continen derivados de hidroxianilina para combatir hongos daninos para las plantas y metodo para combatirlos con aplicacion de dichas composiciones
AR005532A1 (es) Compuestos de dihalopropeno, las composiciones insecticidas/acaricidas que los contienen y los intermediarios de sintesis de dichos compuestos
ES2152328T3 (es) Antagonistas del receptor del fibrinogeno.
ES2150461T3 (es) Derivados de amidinofenilalanina, proceso para su preparacion, su empleo y agentes que los contienen como anticoagulantes.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 880519

Country of ref document: ES